Management Team

N. Scott Fine
Chairman of the Board and Chief Executive Officer

N. Scott Fine has been a Director of the Company since February 2014 and became our Chief Executive Officer on September 14, 2015.  From 2004 until 2014, he was a principal at Scarsdale Equities, an investment banking firm located in New York City. Mr. Fine has been involved in investment banking for over 35 years, working on a multitude of debt and equity financings, buy and sell side M&A, strategic advisory work and corporate restructurings. Much of his time has been focused on transactions in the healthcare and consumer products area. Mr. Fine has led global transactions in healthcare, including medical devices, generic pharmaceuticals, and genetics. He also worked with The Tempo Group of Jakarta, Indonesia when Mr. Fine and his family resided in Jakarta. Mr. Fine was Chairman of the Board of The Global Virus Network (GVN), and he also was the lead investment banker on the initial public offering of Green Mountain Coffee Roasters, Inc. and Central European Distribution Corporation (“CEDC”), a multi-billion-dollar alcohol company. Mr. Fine continued his involvement with CEDC serving as a director from 1996 until 2014, during which time he led the CEDC Board in its successful efforts in 2013 to restructure the company through a pre-packaged Chapter 11 process whereby CEDC was acquired by the Russian Standard alcohol group.  Recently, Mr. Fine served as Vice Chairman and Chairman of the Restructuring Committee of Pacific Drilling from 2017 to 2018 where he successfully led the independent directors to a successful reorganization. He also served as sole director of Better Place Inc. from 2013 until 2015. In his role there, Mr. Fine successfully managed the global wind down of the company in a timely and efficient manner which was approved by both the Delaware and Israeli Courts.

Mr. Fine currently serves on the board of directors of Kenon Holdings Ltd. (NYSE: KEN).  Mr. Fine also devotes time to several non-profit organizations, including through his service on the Board of Trustees for the IWM American Air Museum in Britain.  Mr. Fine has been a guest lecturer at Ohio State University’s Moritz School of Law.

Mr. Fine’s relationships within the financial community in New York and around the world, as well as his significant experience with equity and debt financing, make him a valuable contributor as a Director.  Mr. Fine was appointed to the Board of Directors in connection with a private placement of Common Stock by the Company in February 2014 and has the right to be nominated to our Board (or to have a representative nominated to our Board) for up to seven years from the date of that offering.  Mr. Fine is the father of Joshua M. Fine, our Chief Financial Officer.

Dr. Sharon H. Hrynkow
Chief Scientific Officer, Senior Vice President of Medical Affairs

Dr. Hrynkow was appointed by the Board of Directors in this role in September 2015 to lead the company's clinical and scientific program. Her leadership roles over the past twenty years include service as a Senior Executive at the National Institutes of Health (NIH), where she was the Deputy Director and Acting Director of the Fogarty International Center, the focal point for international research and training and for diplomatic relations for the NIH. Dr. Hrynkow also served as Associate Director of the National Institute on Environmental Health Sciences and Senior Advisor to the NIH Deputy Director. Since 2012, Dr. Hrynkow has been the President of the Global Virus Network, a non-profit organization working to combat pandemic viral disease.

A developmental neuroscientist by training, Dr. Hrynkow has worked passionately to advance science for the benefit of society. She serves on many advisory committees for national and international organizations, and has been recognized for her contributions to global health and global science by scientific and political leaders and organizations, including with the US President's Merit Award for Senior Executives, the Order of Merit from the King of Norway and elected Fellow of the American Association for the Advancement of Science. She is an elected member of the Council on Foreign Relations.

Dr. Jeffrey L. Tate
Director, Chief Operating Officer and Chief Quality Officer

Dr. Tate is a seasoned executive with more than 30 years of experience in the biotechnology, pharmaceutical and nutritional supplements industries including: branded generic drugs, intellectual property strategy, product development, and cGMP manufacturing. He is intimately familiar with food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, experienced in implementation of all aspects of regulatory compliance and in successfully communicating with regulatory agency representatives.

Dr. Tate has successfully established integrated regulatory compliance programs resulting in timely, cost effective corporate-wide compliance, meeting regulatory agency requirements and customer expectations. He closely monitors developments in U.S. and international regulations to maintain compliance and identify regulatory and intellectual property strategies for new products and markets. He holds patents and trademarks in material processing and food formulation.

Michael Lisjak

Global Head of Regulatory Affair, Senior Vice President for Business Development

Mike Lisjak is the Global Head of Reg Affairs and Senior Vice President for Business Development at Cyclo Therapeutics Inc. since July 2019. He brings almost 25 years of Regulatory Strategy and Operations expertise within the biopharmaceutical and consulting industries for multiple therapeutic areas including cardiovascular, metabolic, neuroscience and pain and inflammation. Core skills include strategic planning, negotiating and influence, customer focus, and commercial awareness.

Prior to joining Cyclo Therapeutics, Inc., Mr. Lisjak was the Director of Global Reg Affairs at Sanofi leading the Endocrinology and Neuromuscular Rare Disease Area, which then led to a new role as the Head of Global Regulatory Affairs for Established Products and Global Health. Proceeding Sanofi, Mike served as the Global Regulatory Services Lead for Accenture’s Life Sciences group accountable for the growth and strategic oversight for Accenture’s global regulatory offerings, capabilities and go-to-market strategy. Before Accenture, he held multiple leadership roles at Pfizer and Wyeth with responsibility for developing, maintaining and directing global regulatory strategies and resources in the provision of regulatory guidance and deliverables as well as to ensure optimal regulatory interactions with global/regional Health Authorities. Additionally, Mike supported and delivered formal due diligence assessments for priority business development activities as well as led multiple business initiatives to deliver on-time efficiency solutions through assessment and implementation.

Mr. Lisjak is a Pittsburgh, PA native and currently resides with his family in Greenwich, CT. He holds a Bachelor of Science degree from Rochester Institute of Technology in biology and environmental studies.

Full LinkedIn Profile -

Joshua M. Fine
Chief Financial Officer

Mr. Fine has been an investment banking and finance professional for over 13 years. From 2011 until his appointment as the Company’s Chief Financial Officer, Mr. Fine served as the Vice President/Director, Healthcare Capital Markets, of Scarsdale Equities, LLC (“Scarsdale”). Mr. Fine is also currently the Vice President of Finance and Operations for Icagen, Inc., a biotechnology company, a position he has held since 2017. From 2009 until 2011, Mr. Fine served as the Vice President, Capital Markets of Emerging Growth Equities, a boutique investment banking firm. Mr. Fine holds a Bachelor of Arts in Political Science from Hartwick College.